Sp100
PROMISING POTENTIAL FOR MITHRAMYCIN A, A NOVEL EPIGENETIC ANTINEOPLASTIC AGENT, IN CYTOREDUCTIVE SURGERY FOR PERITONEAL COLORECTAL CANCER
Date
May 18, 2024
Presenter
Tracks
Related Products
THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
Transcholedochal laparoscopic bile duct exploration is a challenging procedure. Advanced cirrhosis with portal hypertension is associated with unique set of challenges not limited to increased risk of bleeding and fragile liver…
EPIGENETIC DYSREGULATION AND IMMUNE CELL INFILTRATION IN THE PANCREATIC NEUROENDOCRINE TUMOR (PNET) MICROENVIRONMENT: AN IMMUNOHISTOCHEMISTRY (IHC) ANALYSIS
BACKGROUND: DNA Methyltransferase inhibitors (DNMTi) have been found to increase the immunogenicity of cancer cells, reshaping the immune tumor microenvironment while directly reprogramming immune cells…
RIGHT POSTERIOR BILE DUCT INJURY RECONSTRUCTION WITH ROBOTIC RY HEPATICOJEJUNOSTOMY
Right posterior bile duct injury with disconnected duct syndrome creates diagnostic challenges for many endoscopists and radiologists. The diagnosis and treatment are often delayed…
PROMISING POTENTIAL FOR MITHRAMYCIN A, A NOVEL EPIGENETIC ANTINEOPLASTIC AGENT, IN CYTOREDUCTIVE SURGERY FOR PERITONEAL COLORECTAL CANCER
The benefit of hyperthermic intraperitoneal chemotherapy, in addition to cytoreductive surgery for colorectal cancer, is debated and warrants the assessment of novel therapeutic agents. Colorectal cancer is known to have aberrant epigenetic dysregulation to silence tumor suppressor gene expression…